---
title: "Kingchem released its 2024 annual performance, with a net profit attributable to the parent company of 38.6093 million yuan, a decrease of 77.76%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237159585.md"
description: "Kingchem released its 2024 annual report, with operating revenue of 497 million yuan, a year-on-year decrease of 35.19%; net profit attributable to shareholders was 38.6093 million yuan, a year-on-year decline of 77.76%; net profit excluding non-recurring gains and losses was 17.3625 million yuan, a year-on-year decrease of 89.66%. The basic earnings per share were 0.32 yuan, and it plans to distribute a cash dividend of 4.00 yuan (including tax) for every 10 shares to all shareholders"
datetime: "2025-04-23T11:23:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237159585.md)
  - [en](https://longbridge.com/en/news/237159585.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237159585.md)
generator: "portal-rs"
---

# Kingchem released its 2024 annual performance, with a net profit attributable to the parent company of 38.6093 million yuan, a decrease of 77.76%

According to the Zhitong Finance APP, Kingchem (301509.SZ) released its annual report for 2024, showing an operating income of 497 million yuan, a year-on-year decrease of 35.19%. The net profit attributable to shareholders of the listed company was 38.6093 million yuan, a year-on-year decrease of 77.76%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 17.3625 million yuan, a year-on-year decrease of 89.66%. The basic earnings per share were 0.32 yuan. In addition, it plans to distribute a cash dividend of 4.00 yuan (including tax) for every 10 shares to all shareholders

### Related Stocks

- [301509.CN](https://longbridge.com/en/quote/301509.CN.md)

## Related News & Research

- [Chinese Pharma Companies Plan Hong Kong Listings](https://longbridge.com/en/news/297979501.md)
- [BioGaia (OM:BIOG B) Could Be 26% Undervalued Following Its Recordati Deal](https://longbridge.com/en/news/298111133.md)
- [Entertainment platform aTwist launches with microseries as Hollywood chases mobile viewers](https://longbridge.com/en/news/297894583.md)
- [UBL: Premiumization and regulatory reforms fuel strong growth and margin expansion ambitions](https://longbridge.com/en/news/297872232.md)
- [Orum to begin Phase I trial of ORM-1153 after FDA clearance](https://longbridge.com/en/news/298030380.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**